TEM Congressional Stock Trades
Tempus AI, Inc. - Class A Common Stock (TEM)
Last disclosed trade Jan 16
Every disclosed trade in TEM by members of Congress under the STOCK Act, parsed by Coldpine. Informational only, sourced from public filings. Not investment advice.
Sample · the intelligence layer
Nancy Pelosi · Bought $TEM · Jan 14 · $50K–$100K
Coldpine’s read
Pelosi's spouse purchased 50 call options on Tempus AI, a healthcare diagnostics and AI company, with a $20 strike expiring January 2026. The 3-day disclosure lag is fast, meaning the market may not have fully absorbed the filing. No other members traded this name within 30 days, and the leveraged options structure amplifies exposure relative to a comparable equity position.
Every disclosed trade in the database gets this treatment: a four-factor score and a written read from Coldpine’s AI-based analysis. Informational only, not investment advice. Create a free account for every scored trade →
Follow $TEM
Get notified when any member of Congress trades $TEM. Free, no card, no spam.
The record on $TEM
Coldpine has parsed 3 disclosed trades in $TEM by 2 members of Congress, drawn from 3 periodic transaction reports dated Jan 14, 2025 through Jan 16, 2026. All of them came from House members, filed 2 by Democrats and 1 by Republicans.
Of the 3 trades with a known filing lag, every one was reported inside the STOCK Act's 45-day window. The median lag was 7 days. The longest was 31 days: a $TEM purchase by Rob Bresnahan dated May 9, 2025, disclosed Jun 9, 2025. How late filing is measured across all of Congress is in the late-filers study.
2 of the 2 trades that list an account holder (100%) were reported under a spouse, dependent child, or joint account rather than the member directly.
Nancy Pelosi filed the most $TEM purchases (2).
Members who trade TEM
Recent disclosed trades in TEM
| Date | Member | Type | Amount |
|---|---|---|---|
| Jan 16 | Nancy Pelosi(CA) | buy | $50K–$100K |
| May 9 | Rob Bresnahan(PA) | buy | $1K–$15K |
| Jan 14 | Nancy Pelosi(CA) | buy | $50K–$100K |
Data sourced from public STOCK Act disclosures. Coldpine is a publisher of intelligence on congressional disclosures, not an investment adviser. See full history and scores, free with an account →